Should We Increase Panel Testing for All Breast Cancer Patients?

Peter Beitsch, Surgical Oncologist Dallas, TX

Amy Taylor, Genetic Counselor at Cambridge University Hospitals

Andrea Forman, Genetic Counselor, UK


0:00 NCCN guidelines out of date

6:03 Which genes should be offered and how?

11:15 Where is the long term care for the patient?

19:11 There is an argument for population screening, but we’re not there yet.

22:41 The cholesterol test argument

28:24 Tests cost less now—how does that change things?

33:18 What are we afraid of--that genetics mean something?

It’s a hot question in the field today. Recently several studies arguing for increased testing for all breast cancer patients have been published in leading oncology journals.

Peter Beitsch is a breast cancer surgeon in Dallas Texas and co-author of one such study in the Journal of Clinical Oncology. He says that NCCN guidelines were created when tests were much more expensive and in an outdated context and that many patients are going under-diagnosed today.

Amy Taylor co-authored a letter to the editor hitting back against Peter’s paper, arguing that the tests he is promoting are not the right ones. She’s a genetic counselor at Cambridge University Hospitals.

Andrea Forman is also a genetic counselor. She is concerned about the long term care of the patients and questions whether we have the infrastructure to implement such increased testing now.

Join us for a lively back and forth on the state of breast cancer testing today.